|
Mitoxantrone Clinical Trials
6 actively recruiting trials across 3 locations
Also known as: Dihydroxyanthracenedione, MIT, Mitozantrone, Novantrone
Pipeline
Phase 1: 2Phase 3: 1Phase 1/2: 2Phase 2/3: 1
Top Sponsors
- University of Washington1
- University of Colorado, Denver1
- University of Birmingham1
- Tanja Andrea Gruber1
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1
Indications
- Cancer6
- Refractory Mixed Phenotype Acute Leukemia2
- Refractory Acute Myeloid Leukemia2
- Refractory Acute Undifferentiated Leukemia1
- Refractory Acute Leukemia of Ambiguous Lineage1
Other2 trials
Seattle, Washington2 trials
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Fred Hutch/University of Washington Cancer Consortium
Phase 1
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Fred Hutch/University of Washington Cancer Consortium
Phase 1/2
Phoenix, Arizona1 trial
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Phoenix Children's Hospital
Phase 1/2
Aurora, Colorado1 trial
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
University of Colorado Hospital
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.